

## Correspondence

**Early-onset generalized pustular psoriasis is representative of autoinflammatory keratinization diseases**

To the Editor:

I read with great interest the article titled “Clinical and genetic differences between pustular psoriasis subtypes” by Twelves et al.<sup>1</sup> The authors studied a large number of patients with pustular psoriasis, including those with generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP), and acrodermatitis continua of Hallopeau (ACH), clinically and genetically. They revealed significant clinical and genetic differences between PPP and GPP.<sup>1</sup>

*IL36RN* mutant alleles are associated with a phenotypic spectrum of pustular psoriasis that includes ACH and PPP, as well as GPP.<sup>2</sup> Twelves et al<sup>1</sup> showed that the proportion of patients carrying *IL36RN* mutations is higher in GPP (23.7%) and ACH (18.2%) than in PPP (5.2%).

Concerning the concurrence of psoriasis vulgaris (PV) in patients with pustular psoriasis, Twelves et al<sup>1</sup> mentioned that no consistent effect of *IL36RN* mutations was seen on PV concurrence in their study. On this point, we previously reported contrary data that most Japanese patients with GPP without PV concurrence have *IL36RN* mutations.<sup>3</sup> In addition, Hussain et al<sup>4</sup> examined 233 patients with GPP and defined a clinical triad (early onset, systemic inflammation, and absence of concurrent PV) to prioritize patients with GPP for *IL36RN* mutation screening. Li et al<sup>5</sup> reported that Han patients with GPP without PV concurrence showed a much higher *IL36RN* mutation frequency than did Han patients with GPP with PV concurrence. Thus, the absence of PV concurrence is apparently associated with

autoinflammatory pathogenesis due to deficiency of the IL-36 receptor antagonist (IL36Ra) in GPP.

As for the age of onset in pustular psoriasis cases, Twelves et al<sup>1</sup> showed that *IL36RN* mutations have dose-dependent effects on the age of onset in GPP. I agree with Twelves et al<sup>1</sup> regarding the association between *IL36RN* mutations and the early age of GPP onset. As mentioned above, Hussain et al<sup>4</sup> previously revealed that patients with early-onset GPP frequently have *IL36RN* mutations. In addition, Mössner et al<sup>6</sup> reported a significant correlation between *IL36RN* mutations and early onset in patients with GPP.

I summarized the reported data that suggest positive correlations between *IL36RN* mutations and early-onset GPP or GPP without PV concurrence (Table I). Taking these data into consideration, I consider that early-onset GPP without PV concurrence often has an autoinflammatory pathogenesis due to *IL36RN* mutations.

Recently, the umbrella term “autoinflammatory keratinization diseases” (AIKDs) has been proposed.<sup>7</sup> AIKDs encompass inflammatory keratinization disorders with autoinflammatory pathogenesis. The primary and main inflammation sites of AIKDs are the epidermis and the upper dermis, where hyperkeratosis is induced by the inflammation. The hyperactivation of innate immunity (autoinflammation) due to certain genetic factors including deficiency of IL36Ra plays an important role in the pathogenesis of AIKD.<sup>7</sup> From its autoinflammatory pathogenic mechanisms, pustular psoriasis due to *IL36RN* mutations is now regarded as an AIKD.<sup>7</sup>

In this context, patients with early-onset GPP without PV concurrence who often have an autoinflammatory pathogenesis due to *IL36RN* mutations might be representative of AIKDs.

**TABLE I.** Data supportive of positive correlations between *IL36RN* mutations and early-onset GPP or GPP without PV concurrence

| Data supportive of correlations between <i>IL36RN</i> mutations and early-onset GPP                                                                                                                                                                                                                                                                                                                  | Reference no. |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| • <i>IL36RN</i> mutation-positive patients show an earlier age of onset. ( <i>IL36RN</i> mutation-positive patients with GPP n = 49; mutation-negative patients n = 166; $P = 5.9 \times 10^{-7}$ .)                                                                                                                                                                                                 | 4             |
| • The mean age of onset in <i>IL36RN</i> mutation heterozygotes exceeds that in patients with biallelic mutations. (Patients with GPP with heterozygous <i>IL36RN</i> mutations n = 18; patients with GPP with biallelic <i>IL36RN</i> mutations n = 49; $P = 6.0 \times 10^{-4}$ .)                                                                                                                 | 4             |
| • A strong association between biallelic <i>IL36RN</i> mutations and early age of onset is observed. (Patients with GPP with biallelic <i>IL36RN</i> mutations n = 15; mutation-negative patients with GPP n = 41; $P = 7.4 \times 10^{-4}$ .)                                                                                                                                                       | 6             |
| • Patients with 1 or 2 <i>IL36RN</i> mutations have a significantly younger age of onset than do <i>IL36RN</i> mutation-negative patients. (Patients with GPP with 1 or 2 <i>IL36RN</i> mutations n = 20; mutation-negative patients with GPP n = 41; $P = 6.9 \times 10^{-3}$ .)                                                                                                                    | 6             |
| • <i>IL36RN</i> mutations are significantly associated with early age of onset. ( <i>IL36RN</i> mutation-positive patients with GPP n = 45; mutation-negative patients n = 145; $P = .003$ .)                                                                                                                                                                                                        | 1             |
| Data supportive of correlations between <i>IL36RN</i> mutations and GPP without PV concurrence                                                                                                                                                                                                                                                                                                       |               |
| • Patients without PV concurrence show a higher <i>IL36RN</i> mutation frequency than do patients with PV concurrence. (Patients with GPP without PV concurrence n = 11 [9 <i>IL36RN</i> mutation-positive patients and 2 mutation-negative patients]; patients with GPP with PV concurrence n = 20 [3 <i>IL36RN</i> mutation-positive patients and 17 mutation-negative patients]; $P < .01$ .)     | 3             |
| • Significantly lower concurrence of PV in <i>IL36RN</i> mutation-positive patients than that in <i>IL36RN</i> mutation-negative patients is observed. ( <i>IL36RN</i> mutation-positive patients with GPP n = 49; mutation-negative patients n = 166; $P = 5.0 \times 10^{-4}$ .)                                                                                                                   | 4             |
| • Patients without PV concurrence exhibit a higher <i>IL36RN</i> mutation frequency than do patients with PV concurrence. (Patients with GPP without PV concurrence n = 24 [19 <i>IL36RN</i> mutation-positive patients and 5 mutation-negative patients]; patients with GPP with PV concurrence n = 19 [7 <i>IL36RN</i> mutation-positive patients and 12 mutation-negative patients]; $P < .05$ .) | 5             |

A better understanding of the pathogenesis of early-onset GPP as an AIKD may provide an important clue for the innovation of novel targeted therapies.

*Masashi Akiyama, MD, PhD*

From the Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. E-mail: [makiyama@med.nagoya-u.ac.jp](mailto:makiyama@med.nagoya-u.ac.jp).

Disclosure of potential conflicts of interest: The author declares that he has no relevant conflicts of interest.

## REFERENCES

- Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic differences between pustular psoriasis subtypes. *J Allergy Clin Immunol* [Epub ahead of print]. <https://doi.org/10.1016/j.jaci.2018.06.038>.
- Setta-Kaffetzi N, Navarini AA, Patel VM, Pullabhatla V, Pink AE, Choon SE, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. *J Invest Dermatol* 2013;133:1366-9.
- Sugiura K, Takemoto A, Yamaguchi M, Takahashi H, Shoda Y, Mitsuma T, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. *J Invest Dermatol* 2013;133:2514-21.
- Hussain S, Berki DM, Choon SE, Burden AD, Allen MH, Arostegui JI, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. *J Allergy Clin Immunol* 2015;135:1067-70.
- Li Z, Yang Q, Wang S. Genetic polymorphism of IL36RN in Han patients with generalized pustular psoriasis in Sichuan region of China: a case-control study. *Medicine (Baltimore)* 2018;97:e11741.
- Mössner R, Wilsmann-Theis D, Oji V, Gkogkolou P, Löhr S, Schulz P, et al. The genetic basis for most patients with pustular skin disease remains elusive. *Br J Dermatol* 2018;178:740-8.
- Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization diseases. *J Allergy Clin Immunol* 2017;140:1545-7.

<https://doi.org/10.1016/j.jaci.2018.11.009>